Journal
CELL
Volume 182, Issue 3, Pages 713-+Publisher
CELL PRESS
DOI: 10.1016/j.cell.2020.06.008
Keywords
-
Categories
Funding
- National Program on Key Research Project of China [2020YFA0707500, 2016YFD0500301, 2017YFC0840300, 2020YFC0842100]
- National Natural Science Foundation of China (NSFC) [31971126]
- CAMS Initiative for Innovative Medicine of China [2016I2M-2-006]
- Beijing Science and Technology Plan [Z201100005420014]
- National Mega Projects of China for Major Infectious Diseases [2017ZX10304402, 2016ZX10004001-003]
Ask authors/readers for more resources
The coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) threatens global public health. The development of a vaccine is urgently needed for the prevention and control of COVID-19. Here, we report the pilot-scale production of an inactivated SARS-CoV-2 vaccine candidate (BBIBP-CorV) that induces high levels of neutralizing antibodies titers in mice, rats, guinea pigs, rabbits, and nonhuman primates (cynomolgus monkeys and rhesus macaques) to provide protection against SARS-CoV-2. Two-dose immunizations using 2 mg/dose of BBIBP-CorV provided highly efficient protection against SARS-CoV-2 intratracheal challenge in rhesus macaques, without detectable antibodydependent enhancement of infection. In addition, BBIBP-CorV exhibits efficient productivity and good genetic stability for vaccine manufacture. These results support the further evaluation of BBIBP-CorV in a clinical trial.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available